SanBio Names Greg Gillas New SVP of Human Resources and Corporate Services

Mountain View, Calif.—September 7, 2016—SanBio, Inc., a scientific leader in regenerative medicine for neurological disorders, today announced the appointment of Greg Gillas as Senior Vice President of Human Resources and Corporate Services. In this role, Greg will be responsible for human resources globally, and information technology and corporate services in the U.S.

Mr. Gillas is an industry veteran with more than 20 years of human resources experience in public companies. He most recently served as the Vice President of Compensation and Benefits at AMD, an international technology company. Prior to that, he spent 12 years at Hewlett-Packard, in a variety of roles, ending as Vice President and Managing Partner of Global Operations for Hewlett-Packard Technology Consulting. Mr. Gillas received his bachelor's degree in Mathematics from Dickinson College.

"I believe that SanBio has the potential to make a significant, positive impact on survivors of stroke and traumatic brain injury, and I'm excited to be a part of their innovative team," said Gillas. "As SanBio continues to grow, I believe my experience will enable SanBio to attract and retain the best talent in the industry."

"We're delighted to welcome Greg Gillas," said Keita Mori, SanBio's Chief Executive Officer. "His experience in supporting multibillion-dollar company operations, as well as managing high-growth divisional operations, will help SanBio to become a global leader in regenerative medicine. Greg has the vision and entrepreneurial drive to work well in the culture of corporate and personal growth we're building at SanBio. I look forward to working with Greg closely in the months and years to come."

Mr. Gillas assumed his position at SanBio on August 29.

About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke. SanBio also began a global Phase 2 clinical trial for treatment of motor impairment resulting from traumatic brain injury. More information about SanBio, Inc. is available at http://san-bio.com.

Media contact:
Meredith Gallagher
(612) 455-1724
Meredith.Gallagher@padillacrt.com